Lutetium (177Lu) oxodotreotide

（177镥）镥氧奥曲肽

Report date: 2026/05/23 20:00:57
NMEFirst In Class

Base Information

Drug NameLutetium (177Lu) oxodotreotide
Drug Alias Name镥[177Lu]氧奥曲肽177Lu-[DOTA0,Tyr3]octreotate177Lu-DOTA0-Tyr3-OctreotateLutetium Lu 177 dotatateLutetium Dotatate LU-177 +[15] 
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionSomatostatin receptor 2 antagonistsPositron-emission tomography enhancers
TargetsSomatostatin receptor 2
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)Medullary thyroid cancer (MTC)Metastatic breast cancer +[22] 
Global Approved IndicationsNeuroendocrine Tumors
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2017/09/26
Country/TerritoryBelgiumCanadaUnited States +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesAdvanced Accelerator Applications Sa
China Registration ClassN/A

Develop Information

Active CompaniesAdvanced Accelerator Applications SaMednor Medical Technology Group Co LtdC-Ray Therapeutics (Chengdu) Co Ltd +[18] 
Inactive CompaniesIstituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST SRLThe University Of IowaThe University Of Chicago +[6] 
Active IndicationsPancreatic neuroendocrine tumors (pNET)Medullary thyroid cancer (MTC)Metastatic breast cancer +[18] 
Inactive IndicationsPituitary NeoplasmsPancreatic NeoplasmsAdenoma, Islet Cell +[4] 

Other Information

ATC CodeV10XX04
Related LinksKEGG